| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2135060 | Experimental Hematology | 2008 | 9 Pages |
Abstract
IL-15 and CpG ODN A enhance rituximab-mediated ADCC against B-cell lymphoma. Under these conditions, NK cells seem to be the main effector cells mediating ADCC. These findings suggest that these agents could be used as adjuvants in combination with rituximab for patients with B-cell lymphoma.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Esther Moga, Eva Alvarez, Elisabet Cantó, Silvia Vidal, José Luis RodrÃguez-Sánchez, Jorge Sierra, Javier Briones,